CliffBio
small molecule

ZEPATIER

ELBASVIR; GRAZOPREVIR

Loss of exclusivityMay 2031latest FDA-listed patent expiry
CompanyMERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC

Drug detail

Brand nameZEPATIER
Active ingredientELBASVIR; GRAZOPREVIR
Strength50MG;100MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2016
Marketing statusDISCN

Listed patents

PatentExpiresType
8871759May 2031substance, product
7973040July 2029substance, product

More from MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ZEPATIER patent cliff — loss of exclusivity May 2031 | CliffBio